MADRID (Reuters) - An abrupt loss of power generation at a substation in Granada, followed by failures seconds later in Badajoz and Seville, triggered an unprecedented blackout across Spain and ...
Hosted on MSN
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug
The Danish pharmaceutical giant on Monday said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop 15.7% of their weight after 68 weeks.
Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the FDA for approval on Thursday. Eli Lilly’s LLY drug is called orforglipron.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results